Utah Medical Products, Inc. ( UTMD ) NASDAQ Global Select

Cena: 58.44 ( 1.66% )

Aktualizacja 07-03 19:04
NASDAQ Global Select
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 169
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 94%
Ilość akcji: 3 629 530
Debiut giełdowy: 1999-03-08
WWW: https://www.utahmed.com
CEO: Mr. Kevin L. Cornwell
Adres: 7043 South 300 West
Siedziba: 84047-1048 Midvale
ISIN: US9174881089
Opis firmy:

Utah Medical Products, Inc. opracowuje, produkuje i dystrybuuje urządzenia medyczne dla branży opieki zdrowotnej. Firma oferuje akcesoria do monitorowania płodu, systemy dostarczania wspomagane próżniowo oraz inne narzędzia do pracy i dostawy; Kaptury oddechowe dla niemowląt z dyspozycją; oraz Deltran plus systemy monitorowania ciśnienia krwi. Zapewnia również cewniki naczyń pępowinowych Gesco; Zestawy dializy otrzewnej do dializy; Pala-nate silikonowe urządzenia doustne; URI-Cath Systems drenażu moczu; Nutri-Cath \ Nutri-Lok Urządzenie; Zestawy do próbkowania lędźwiowego mielo-nate; Filtry jednorazowe hemo-nate; oraz procedura cewnikowania Tray instrumentów i materiałów eksploatacyjnych. Ponadto firma oferuje system LETZ do wycięcia śródnabłonkowej nowotworu szyjki macicy i innych zmian narządów płciowych; Generatory Finesse+; Elektrody pętli, piłki i igły; Ewakuatorzy filtrów; inne elektrody specjalne i materiały eksploatacyjne oraz narzędzia ginekologiczne; Trocars femcare, kaniule, instrumenty laparoskopowe i akcesoria; oraz urządzenia do uosobienia i optymiarów elektrochirurgicznych. Ponadto zapewnia Filshie Clip żeńskie urządzenia antykoncepcyjne; Pathfinder plus endoskopowe urządzenia do nawadniania; cewnikowanie suprapubiczne; Systemy leczenia nietrzymania moczu w moczu; Endocurette, kusie do pobierania próbek tkanki endometrium macicy; TVUS/HSG-Cath do oceny nieprawidłowego lub dysfunkcyjnego krwawienia macicy i innych nieprawidłowości macicy; i narzędzie luminowe do manipulowania macicą w procedurach laparoskopowych. Ponadto firma oferuje Deltran, przetwornik do dyspozycji; oraz akcesoria do monitorowania ciśnienia, komponenty i inne uformowane części. Obsługuje noworodkowe jednostki intensywnej terapii, wydziały pracy i dostawy, centra zdrowia kobiet w szpitalach, kliniki ambulatoryjne oraz biura lekarzy poprzez bezpośrednią obsługę klienta i siłę sprzedaży, niezależnych konsultantów i przedstawicieli producentów. Firma została zarejestrowana w 1978 roku i ma siedzibę w Midvale w stanie Utah.

Wskaźniki finansowe
Kapitalizacja (USD) 189 825 392
Aktywa: 129 694 000
Cena: 58.44
Wskaźnik Altman Z-Score: 26.5
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 1
P/E: 15.4
Ilość akcji w obrocie: 94%
Średni wolumen: 17 550
Ilość akcji 3 248 210
Wskaźniki finansowe
Przychody TTM 44 078 000
Zobowiązania: 5 497 000
Przedział 52 tyg.: 51.26 - 77.33
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 3.8
P/E branży: 29.9
Beta: 0.08
Raport okresowy: 2025-07-23
WWW: https://www.utahmed.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Kevin L. Cornwell Chairman, Chief Executive Officer, President & Secretary 510 570 1947
Mr. Brian L. Koopman Principal Financial Officer, Accounting Manager & Controller 152 776 1970
Mark L. Fox Vice President of Marketing 0 0
Marcena H. Clawson Head of Corporate Sales 0 0
Wiadomości dla Utah Medical Products, Inc.
Tytuł Treść Źródło Aktualizacja Link
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accessnewswire.com 2025-05-06 14:00:00 Czytaj oryginał (ang.)
Stock Picks From Seeking Alpha's April 2025 New Analysts In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside. seekingalpha.com 2025-05-06 12:00:00 Czytaj oryginał (ang.)
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1% UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position. zacks.com 2025-05-05 18:35:31 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025 SALT LAKE CITY, UT / ACCESS Newswire / April 29, 2025 / In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. Summary of results. accessnewswire.com 2025-04-29 13:00:00 Czytaj oryginał (ang.)
Utah Medical Products: Quietly Profitable--A Deep Value Gem Hiding In The Open Utah Medical Products develops and manufactures medical devices focused on women's health, obstetrics, gynecology, and blood pressure monitoring. The company's stock price has declined due to a drop in sales from a key U.S. customer, weaker performance in international markets, and ongoing litigation. Despite recent challenges, the company has a consistent track record of profitability, a fortress balance sheet, and a disciplined capital allocator in the CEO. seekingalpha.com 2025-04-16 14:58:20 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accessnewswire.com 2025-02-04 12:00:00 Czytaj oryginał (ang.)
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5% UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025. zacks.com 2025-01-31 14:51:08 Czytaj oryginał (ang.)
UTMD Reports Year 2024 and Fourth Quarter Financial Performance SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market. accessnewswire.com 2025-01-28 11:00:00 Czytaj oryginał (ang.)
Utah Medical Products: Favorably Skewed Risk/Reward Profile UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share. seekingalpha.com 2024-12-26 08:33:52 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S. accesswire.com 2024-11-05 12:00:00 Czytaj oryginał (ang.)
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins. zacks.com 2024-10-30 15:16:07 Czytaj oryginał (ang.)
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024 SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. accesswire.com 2024-10-29 11:00:00 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accesswire.com 2024-08-02 14:00:00 Czytaj oryginał (ang.)
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable. zacks.com 2024-07-26 18:46:03 Czytaj oryginał (ang.)
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024 SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. accesswire.com 2024-07-25 13:00:00 Czytaj oryginał (ang.)
Zacks Initiates Coverage of UTMD With Neutral Recommendation Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry. zacks.com 2024-05-28 14:16:05 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / May 7, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on July 5, 2024 to stockholders of record at the close of business on June 14, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accesswire.com 2024-05-07 14:00:00 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024 SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. Summary of results. accesswire.com 2024-04-25 13:00:00 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / February 6, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on April 3, 2024 to stockholders of record at the close of business on March 15, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accesswire.com 2024-02-06 12:00:00 Czytaj oryginał (ang.)
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management's beginning of year projections. globenewswire.com 2024-01-30 11:00:00 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Increases Regular Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023. This is a 1.7% increase over the prior regular quarterly cash dividend. accesswire.com 2023-10-31 12:00:00 Czytaj oryginał (ang.)
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023 SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. globenewswire.com 2023-10-26 13:00:00 Czytaj oryginał (ang.)
Utah Medical Products: Long-Term Positives, But Filshie Clip Overhang Can't Be Ignored Utah Medical Products stock has dropped 14% and is at its lowest point this year due to ongoing lawsuits regarding its Filshie clip system. The lawsuits do pose a risk to UTMD's stock price, and a negative outcome could further impact the company's equity. Despite the risks, UTMD's long-term economics and attractive proposition in multiple markets are bullish features. seekingalpha.com 2023-09-26 05:12:18 Czytaj oryginał (ang.)
Utah Medical Products, Inc. Announces Quarterly Dividend SALT LAKE CITY, UT / ACCESSWIRE / August 1, 2023 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on October 3, 2023 to shareholders of record at the close of business on September 15, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. accesswire.com 2023-08-01 14:00:00 Czytaj oryginał (ang.)
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023 SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections. globenewswire.com 2023-07-25 13:00:00 Czytaj oryginał (ang.)
Utah Medical Products: Earnings Power, Asset Factors Warrant Further Re-Rating Utah Medical Products comes with high returns on capital and projected earnings growth into FY'25. The company has compounded earnings at a rate of 2.8x that of revenue since 2021. Net-net, reiterate buy, eyeing a long-term price target of $223 per share. seekingalpha.com 2023-07-14 21:56:12 Czytaj oryginał (ang.)
Utah Medical Products: Recycling Capital Well, Long-Term Gains On The Table Utah Medical Products: Recycling Capital Well, Long-Term Gains On The Table seekingalpha.com 2023-04-19 08:29:48 Czytaj oryginał (ang.)
Is Utah Medical Products Suitable As A Defensive Overlay In Equity Portfolios? UTMD is a relatively undercovered, unexploited name that historically trades within a narrow trading range, within a defensive sector. With this in mind, we wanted to see how it fits in within a cross-asset balanced portfolio setup. seekingalpha.com 2022-12-06 08:57:05 Czytaj oryginał (ang.)